Literature DB >> 19703748

Combined use of pretest clinical probability score and latex agglutination D-dimer testing for excluding acute deep vein thrombosis.

Takashi Yamaki1, Motohiro Nozaki, Hiroyuki Sakurai, Yuji Kikuchi, Kazutaka Soejima, Taro Kono, Atsumori Hamahata, Kaya Kim.   

Abstract

OBJECTIVE: Currently, the latex agglutination D-dimer assay is widely used for excluding deep vein thrombosis (DVT) but is considered less sensitive than the enzyme-linked immunosorbent assay-based D-dimer test. The purpose of the present study was to determine if a combination of different cutoff points, rather than a single cutoff point of 1.0 microg/mL, on the latex agglutination D-dimer assay and the pretest clinical probability (PTP) score would be able to reduce the use of venous duplex ultrasound (DU) scanning in patients with suspected DVT.
METHODS: The PTP score and D-dimer testing were used to evaluate 989 consecutive patients with suspected DVT before venous DU scanning. After calculating the clinical probability scores, patients were divided into low-risk (< or =0 points), moderate-risk (1-2 points), and high-risk (> or =3 points) pretest clinical probability groups. Receiver operating characteristic (ROC) curve analysis was used to determine the appropriate D-dimer cutoff point for each PTP with a negative predictive value of >98% for a positive DU scan.
RESULTS: There were 886 patients enrolled. The study group included 609 inpatients (68.7%) and 277 outpatients (31.3%). The prevalence of DVT in this series was 28.9%. There were 508 patients (57.3%) classified as low-risk, 237 (26.8%) as moderate-risk, and 141 (14.9%) as high-risk PTP. DVT was identified in 29 patients (5.7%) with low-risk, 118 (49.8%) with moderate-risk, and 109 (77.3%) with high-risk PTP scores. ROC curve analysis was used to select D-dimer cutoff points of 2.6, 1.1, and 1.1 microg/mL for the low-, moderate- and high-risk PTP groups, respectively. In the low-risk PTP group, specificity increased from 48.9% to 78.2% (P < .0001) with use of the different D-dimer cutoff value. In the moderate- and high-risk PTP groups, however, the different D-dimer levels did not achieve substantial improvement. Despite this, the overall use of venous DU scanning could have been reduced by 43.0% (381 of 886) if the different D-dimer cutoff points had been used.
CONCLUSIONS: Combination of a specific D-dimer level with the clinical probability score is most effective in low-risk PTP patients for excluding DVT. In moderate- and high-risk PTP patients, however, the recommended cutoff points of 1.0 microg/mL may be preferable. These results show that different D-dimer levels for patients differing in risk is feasible for excluding DVT using the latex agglutination D-dimer assay.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19703748     DOI: 10.1016/j.jvs.2009.06.059

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  9 in total

Review 1.  Management of Venous Thromboembolisms: Part I. The Consensus for Deep Vein Thrombosis.

Authors:  Kang-Ling Wang; Pao-Hsien Chu; Cheng-Han Lee; Pei-Ying Pai; Pao-Yen Lin; Kou-Gi Shyu; Wei-Tien Chang; Kuan-Ming Chiu; Chien-Lung Huang; Chung-Yi Lee; Yen-Hung Lin; Chun-Chieh Wang; Hsueh-Wei Yen; Wei-Hsian Yin; Hung-I Yeh; Chern-En Chiang; Shing-Jong Lin; San-Jou Yeh
Journal:  Acta Cardiol Sin       Date:  2016-01       Impact factor: 2.672

2.  Appropriate use of D-dimer testing can minimize over-utilization of venous duplex ultrasound in a contemporary high-volume hospital.

Authors:  Albeir Y Mousa; Mike Broce; Gurpreet Gill; Maher Kali; Michael Yacoub; Ali F AbuRahma
Journal:  Ann Vasc Surg       Date:  2014-10-05       Impact factor: 1.466

3.  Evaluation of the usefulness of a D dimer test in combination with clinical pretest probability score in the prediction and exclusion of Venous Thromboembolism by medical residents.

Authors:  Tarek Owaidah; Nahlah AlGhasham; Saad AlGhamdi; Dania AlKhafaji; Bandar ALAmro; Mohamed Zeitouni; Fawaz Skaff; Hazzaa AlZahrani; Adher AlSayed; Naser ElKum; Mahmoud Moawad; Ahmed Nasmi; Mohannad Hawari; Khalid Maghrabi
Journal:  Thromb J       Date:  2014-11-28

4.  Prevalence of Asymptomatic Venous Thromboembolism in Depressive Inpatients.

Authors:  Masahiro Takeshima; Hiroyasu Ishikawa; Yoshiaki Umeta; Mizuki Kudoh; Akise Umakoshi; Kazuhisa Yoshizawa; Yu Ito; Tomoko Hosoya; Ko Tsutsui; Hidenobu Ohta; Kazuo Mishima
Journal:  Neuropsychiatr Dis Treat       Date:  2020-02-26       Impact factor: 2.570

5.  Severity of Depressive Symptoms is Associated with Venous Thromboembolism in Hospitalized Patients with a Major Depressive Episode.

Authors:  Kazuhisa Yoshizawa; Masahiro Takeshima; Sayaka Ishino; Masaya Ogasawara; Dai Fujiwara; Yu Itoh; Aya Imanishi; Hidenobu Ohta; Kazuo Mishima
Journal:  Neuropsychiatr Dis Treat       Date:  2021-09-21       Impact factor: 2.570

Review 6.  The diagnosis and treatment of venous thromboembolism in asian patients.

Authors:  Kang-Ling Wang; Eng Soo Yap; Shinya Goto; Shu Zhang; Chung-Wah Siu; Chern-En Chiang
Journal:  Thromb J       Date:  2018-01-18

7.  Incidence of venous thromboembolism in psychiatric inpatients: a chart review.

Authors:  Masahiro Takeshima; Hiroyasu Ishikawa; Kazumi Shimizu; Takashi Kanbayashi; Tetsuo Shimizu
Journal:  Neuropsychiatr Dis Treat       Date:  2018-05-23       Impact factor: 2.570

8.  High Signal Intensity on Diffusion-Weighted Images Reflects Acute Phase of Deep Vein Thrombus.

Authors:  Toshihiro Gi; Yasuyoshi Kuroiwa; Atsushi Yamashita; Yuko Mizutani; Taketoshi Asanuma; Tosiaki Miyati; Kazunari Maekawa; Murasaki Aman; Takuroh Imamura; Yujiro Asada
Journal:  Thromb Haemost       Date:  2020-08-03       Impact factor: 5.249

9.  The Usefulness of the Combination of D-Dimer and Soluble Fibrin Monomer Complex for Diagnosis of Venous Thromboembolism in Psychiatric Practice: A Prospective Study.

Authors:  Masahiro Takeshima; Hiroyasu Ishikawa; Masaya Ogasawara; Munehiro Komatsu; Dai Fujiwara; Yu Itoh; Yuki Wada; Yuki Omori; Hidenobu Ohta; Kazuo Mishima
Journal:  Vasc Health Risk Manag       Date:  2021-05-21
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.